Gallbladder hemorrhage during orally administered edoxaban therapy: a case report
Abstract Background Edoxaban is an orally administered anticoagulant treatment that is used in patients with cerebral infarction, venous thrombosis, or other conditions, with a reported incidence of gastrointestinal hemorrhage at approximately 1%. We encountered the rare case of a patient who develo...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13256-019-2328-9 |
id |
doaj-5df24e543e544c4792dbf63ae948a150 |
---|---|
record_format |
Article |
spelling |
doaj-5df24e543e544c4792dbf63ae948a1502020-12-27T12:06:19ZengBMCJournal of Medical Case Reports1752-19472019-12-011311410.1186/s13256-019-2328-9Gallbladder hemorrhage during orally administered edoxaban therapy: a case reportHideya Itagaki0Suzuki Katuhiko1Department of General Surgery, Honjou Daiichi HospitalDepartment of General Surgery, Honjou Daiichi HospitalAbstract Background Edoxaban is an orally administered anticoagulant treatment that is used in patients with cerebral infarction, venous thrombosis, or other conditions, with a reported incidence of gastrointestinal hemorrhage at approximately 1%. We encountered the rare case of a patient who developed a gallbladder hemorrhage after the administration of edoxaban. Case presentation An 86-year-old Japanese woman visited our gastrointestinal department due to the chief complaint of melena lasting for a week. Her medical history included hypertension and embolic cerebral infarction, and she was taking orally administered carvedilol (5 mg/day) and edoxaban (30 mg/day). Her palpebral conjunctiva was pale during a physical examination, indicating the possibility of anemia. Her blood test results confirmed severe anemia with red blood cells at 1.7 × 106/μL and hemoglobin at 4.7 g/dL. An upper gastrointestinal endoscopy revealed bile and fresh blood on the duodenal bulb and in more distal regions; hemobilia was suspected. A computed tomography scan on the ninth hospitalization day confirmed the hemobilia with a gallbladder fundus high-density signal. She was discharged on the 30th day of hospitalization with only fluid therapy and no progression of anemia. Moreover, she underwent a laparoscopic cholecystectomy 1 month after discharge, but the pathologist did not identify false aneurysms or neoplastic lesions. She has not been shown to develop anemia for 5 months after surgery. Conclusions Our case suggests that gallbladder hemorrhage needs to be considered a possible complication for patients on direct oral anticoagulants.https://doi.org/10.1186/s13256-019-2328-9Direct oral anticoagulant (DOAC)EdoxabanGallbladder hemorrhageHemobiliaUpper gastrointestinal hemorrhage |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hideya Itagaki Suzuki Katuhiko |
spellingShingle |
Hideya Itagaki Suzuki Katuhiko Gallbladder hemorrhage during orally administered edoxaban therapy: a case report Journal of Medical Case Reports Direct oral anticoagulant (DOAC) Edoxaban Gallbladder hemorrhage Hemobilia Upper gastrointestinal hemorrhage |
author_facet |
Hideya Itagaki Suzuki Katuhiko |
author_sort |
Hideya Itagaki |
title |
Gallbladder hemorrhage during orally administered edoxaban therapy: a case report |
title_short |
Gallbladder hemorrhage during orally administered edoxaban therapy: a case report |
title_full |
Gallbladder hemorrhage during orally administered edoxaban therapy: a case report |
title_fullStr |
Gallbladder hemorrhage during orally administered edoxaban therapy: a case report |
title_full_unstemmed |
Gallbladder hemorrhage during orally administered edoxaban therapy: a case report |
title_sort |
gallbladder hemorrhage during orally administered edoxaban therapy: a case report |
publisher |
BMC |
series |
Journal of Medical Case Reports |
issn |
1752-1947 |
publishDate |
2019-12-01 |
description |
Abstract Background Edoxaban is an orally administered anticoagulant treatment that is used in patients with cerebral infarction, venous thrombosis, or other conditions, with a reported incidence of gastrointestinal hemorrhage at approximately 1%. We encountered the rare case of a patient who developed a gallbladder hemorrhage after the administration of edoxaban. Case presentation An 86-year-old Japanese woman visited our gastrointestinal department due to the chief complaint of melena lasting for a week. Her medical history included hypertension and embolic cerebral infarction, and she was taking orally administered carvedilol (5 mg/day) and edoxaban (30 mg/day). Her palpebral conjunctiva was pale during a physical examination, indicating the possibility of anemia. Her blood test results confirmed severe anemia with red blood cells at 1.7 × 106/μL and hemoglobin at 4.7 g/dL. An upper gastrointestinal endoscopy revealed bile and fresh blood on the duodenal bulb and in more distal regions; hemobilia was suspected. A computed tomography scan on the ninth hospitalization day confirmed the hemobilia with a gallbladder fundus high-density signal. She was discharged on the 30th day of hospitalization with only fluid therapy and no progression of anemia. Moreover, she underwent a laparoscopic cholecystectomy 1 month after discharge, but the pathologist did not identify false aneurysms or neoplastic lesions. She has not been shown to develop anemia for 5 months after surgery. Conclusions Our case suggests that gallbladder hemorrhage needs to be considered a possible complication for patients on direct oral anticoagulants. |
topic |
Direct oral anticoagulant (DOAC) Edoxaban Gallbladder hemorrhage Hemobilia Upper gastrointestinal hemorrhage |
url |
https://doi.org/10.1186/s13256-019-2328-9 |
work_keys_str_mv |
AT hideyaitagaki gallbladderhemorrhageduringorallyadministerededoxabantherapyacasereport AT suzukikatuhiko gallbladderhemorrhageduringorallyadministerededoxabantherapyacasereport |
_version_ |
1724369386676944896 |